Apr 23 |
Edgewise gets EU orphan drug status for muscular dystrophy drug
|
Apr 23 |
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
|
Apr 15 |
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
|
Mar 28 |
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
|
Mar 27 |
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
|
Mar 5 |
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
|
Feb 28 |
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
|
Feb 26 |
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
|
Feb 22 |
Edgewise Therapeutics Non-GAAP EPS of $0.47
|
Feb 22 |
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|